Lenz Therapeutics Inc LENZ

$2.96 -0.38 (-11.23%)

Valuation

Market cap
93,163,000
Revenue TTM
$19,090,000
Net income TTM
$-82,130,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-430.23%
Debt to equity
0.00

Trading

Volume
951,700
Avg volume
957,912
Day's range
$2.82 – $3.44
Shares out
31,421,000
Stochastic %K
10%
Beta
0.78
Analysts
Moderate Buy
Price target
$14.83

Price

Company profile

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was...

Show more

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 925 7000
Website
https://www.lenz-tx.com
Address
201 Lomas Santa Fe Drive, Suite 300, Solana Beach, United States

Latest news

Stocktwits

dibatista Nov 16, 12:28 PM
$LENZ Google Rrends show Vizz is the market leader, confirming the company's statement that Vizz has ~94% of the eye drop presbyopia market. Patient research and awarenes has increased significanly. And continues to increase.
1 replies
roblake29 Nov 13, 11:29 PM
$LENZ My latest on Lenz Therapeutics. I wish I had more positive things to say on this one. I suggest caution! https://seekingalpha.com/article/4967947-lenz-therapeutics-dont-be-tempted-with-this-value-trap
1 replies
dbears729 Nov 9, 7:06 PM
$LENZ ~$75 million annual savings from the restructuring 👀
1 replies
SLB85 Nov 6, 7:19 PM 0 replies
d_risk Nov 5, 3:13 AM
$LENZ - LENZ Therapeutics Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +213.1% above peer average (37,010 vs 11,819 across 655 peers). LENZ says its board approved a reorganization on Oct. 28 that includes reducing its workforce by approximately 75%. The company says it remains dependent on key managers as it commercializes VIZZ and operates as a public company. #Pharmaceuticals #LeadershipTransition #WorkforceReduction #CommercializationRisk #ProductApproval 🟢 Added 🟠 Removed https://d-risk.ai/LENZ/10-Q/2026-11-03
0 replies
NYTWben Nov 4, 9:17 PM
$LENZ according to the latest filing BML now owns over 6% of $LENZ. BML is an activist hedge fund known for pushing for strategic reviews, or demanding that cash-rich but struggling biotech firms wind down operations to maximize shareholder returns. Wish they would jumped in when this thing was a 20.
3 replies
JRobb66 Nov 4, 10:42 AM
$LENZ they have to go DTC.. doctors make money selling glasses and contacts not writing scripts. They should partner with HIMS and other telegraphy glp1 hair growth etc companies
3 replies
StockScanners Nov 4, 12:55 AM
$LENZ keep watch if this holds above 3.38
0 replies